Literature DB >> 27662313

Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model.

Animesh Alexander Raha1, James W Henderson1, Simon R W Stott1, Romina Vuono1, Simona Foscarin1, Robert P Friedland2, Shahid H Zaman3, Ruma Raha-Chowdhury1.   

Abstract

Neuroinflammation and activation of innate immunity are early events in neurodegenerative diseases including Alzheimer's disease (AD). Recently, a rare mutation in the gene Triggering receptor expressed on myeloid cells 2 (TREM2) has been associated with a substantial increase in the risk of developing late onset AD. To uncover the molecular mechanisms underlying this association, we investigated the RNA and protein expression of TREM2 in APP/PS1 transgenic mice. Our findings suggest that TREM2 not only plays a critical role in inflammation, but is also involved in neuronal cell survival and in neurogenesis. We have shown that TREM2 is a soluble protein transported by macrophages through ventricle walls and choroid plexus, and then enters the brain parenchyma via radial glial cells. TREM2 protein is essential for neuroplasticity and myelination. During the late stages of life, a lack of TREM2 protein may accelerate aging processes and neuronal cell loss and reduce microglial activity, ultimately leading to neuroinflammation. As inflammation plays a major role in neurodegenerative diseases, a lack of TREM2 could be a missing link between immunomodulation and neuroprotection.

Entities:  

Keywords:  Alzheimer’ disease; choroid plexus macrophages; immunomodulation; innate immunity; myelination; neurogenesis; neuroinflammation; neuroplasticity; neuroprotective; soluble TREM2

Mesh:

Substances:

Year:  2017        PMID: 27662313     DOI: 10.3233/JAD-160663

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  31 in total

Review 1.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

2.  Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.

Authors:  Jerel Adam Fields; Brian Spencer; Mary Swinton; Emma Martine Qvale; María J Marquine; Arina Alexeeva; Sarah Gough; Benchawanna Soontornniyomkij; Elvira Valera; Eliezer Masliah; Cristian L Achim; Paula Desplats
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

Review 3.  Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia.

Authors:  William C Kreisl; Ioline D Henter; Robert B Innis
Journal:  Adv Pharmacol       Date:  2017-11-10

Review 4.  Neuroinflammation in Neurodegenerative Disorders-a Review.

Authors:  Martin Schain; William Charles Kreisl
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

5.  Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury.

Authors:  Nicole J Scott-Hewitt; Christopher J Folts; Jessica M Hogestyn; Gavin Piester; Margot Mayer-Pröschel; Mark D Noble
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

6.  Effects of (-)-epicatechin on neuroinflammation and hyperphosphorylation of tau in the hippocampus of aged mice.

Authors:  Viridiana Navarrete-Yañez; Alejandra Garate-Carrillo; Alonso Rodriguez; Patricia Mendoza-Lorenzo; Guillermo Ceballos; Claudia Calzada-Mendoza; Michael C Hogan; Francisco Villarreal; Israel Ramirez-Sanchez
Journal:  Food Funct       Date:  2020-11-17       Impact factor: 5.396

Review 7.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

8.  Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer's pathology.

Authors:  Jean-Vianney Haure-Mirande; Mickael Audrain; Tomas Fanutza; Soong Ho Kim; William L Klein; Charles Glabe; Ben Readhead; Joel T Dudley; Robert D Blitzer; Minghui Wang; Bin Zhang; Eric E Schadt; Sam Gandy; Michelle E Ehrlich
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

9.  Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.

Authors:  Edward N Wilson; Michelle S Swarovski; Patricia Linortner; Marian Shahid; Abigail J Zuckerman; Qian Wang; Divya Channappa; Paras S Minhas; Siddhita D Mhatre; Edward D Plowey; Joseph F Quinn; Cyrus P Zabetian; Lu Tian; Frank M Longo; Brenna Cholerton; Thomas J Montine; Kathleen L Poston; Katrin I Andreasson
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

10.  Acute Trem2 reduction triggers increased microglial phagocytosis, slowing amyloid deposition in mice.

Authors:  Kathleen M Schoch; Lubov A Ezerskiy; Michaela M Morhaus; Riley N Bannon; Andrew D Sauerbeck; Mark Shabsovich; Paymaan Jafar-Nejad; Frank Rigo; Timothy M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.